-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

Benzinga·07/13/2026 09:53:42
语音播报
Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $22.